Summaries of health policy coverage from major news organizations
Gilead Lowers Prices of Antiretrovirals Viread, Truvada in Developing Countries
Gilead Sciences on Monday announced it is lowering the prices of its antiretroviral drugs Viread and Truvada by 31% and 12%, respectively, in 97 developing countries that participate in the company's access program, the AP/Forbes reports (AP/Forbes, 8/29). The company said the no-profit price of a 30-day supply of Viread is now $17 and Truvada costs $26.25 for a one-month supply. The company was able to cut the drugs' prices because of lowered production costs as a result of increased economies of scale, a new plant in the Bahamas and general manufacturing improvements (Reuters, 8/29). The Gilead Access Program provides both public and private not-for-profit groups in developing countries reduced-price drugs to treat HIV/AIDS patients (Gilead release, 8/29).
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.